PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Cell Mol Neurobiol. Author manuscript; available in PMC Jan 1, 2011.
Published in final edited form as:
PMCID: PMC2813927
NIHMSID: NIHMS169749
Metabolic characterization of a mouse deficient in all known leptin receptor isoforms
Olivia Osborn,1 Manuel Sanchez-Alavez,1 Sara E. Brownell,1 Brendon Ross,1 Joe Klaus,1 Jeffrey Dubins,3 Bruce Beutler,2 Bruno Conti,1 and Tamas Bartfai1
1The Harold L. Dorris Neurological Research Institute and Molecular and Integrative Neurosciences Department, La Jolla, CA 92037
2Department of Genetics, The Scripps Research Institute, La Jolla, CA 92037
3Pfizer Research, Groton, CT
*Correspondence and requests for materials should be addressed to: Olivia1/at/scripps.edu (olivia1/at/scripps.edu), The Scripps Research Institute, 10550 North Torrey Pines Road, SR307, La Jolla, CA 92037 USA, Phone: 858.784.9146, Fax: 858.784.9099
We have characterized a newly generated mouse model of obesity, a mouse strain deficient in all five previously described leptin receptor isoforms. These transgenic mice, named the db333/db333 mice, were identified from an ENU mutagenesis screen and carry a point mutation in the seventh exon of the db gene encoding the leptin receptor, resulting in a premature stop codon (Y333Stop) and gene product that lacks STAT signaling domains. db333/db333 mice have a morbidly obese phenotype, with body weights diverging from wild-type as early as 4 weeks of age (P<0.05). To determine the contribution of the short isoforms of the leptin receptor in this metabolic phenotype we performed an extensive metabolic characterization of the db333/db333 mouse in relation to the well characterized db/db mouse lacking only the long form of the leptin receptor. db333/db333 mice have similar endocrine and metabolic parameters as previously described in other leptin receptor transgenic mice including db/db mice that lack only the long isoform of the leptin receptor. However, db333/db333 mice show a subtle trend towards higher body weight, insulin levels, lower oxygen production, carbon dioxide production, respiratory efficiency ratio and temperature than db/db mice suggesting the short isoforms may play an additional role in energy homeostasis.
Keywords: leptin, leptin receptor, Ob-Rb, obesity, db/db, db333/db333, diabetes, insulin resistance
Leptin signaling is an important mediator of feeding behavior, energy homeostasis and normal immune and reproductive function (Halaas, Gajiwala et al. 1995; Pelleymounter, Cullen et al. 1995; Chehab, Lim et al. 1996; Schwartz, Baskin et al. 1996; Loffreda, Yang et al. 1998; Lord, Matarese et al. 1998). Leptin is a 16 kDa cytokine, secreted by adipocytes that is encoded by the ob gene that acts at the hypothalamic level through the leptin receptor (Ob-R) encoded by the db gene. Leptin acts as a feedback signal reflecting the nutritional status of the periphery to suppress feeding and to permit neuroendocrine functions (Ahima, Prabakaran et al. 1996; Ahima, Dushay et al. 1997; Heiman, Ahima et al. 1997; Yu, Kimura et al. 1997). Conversely negative energy balance decreases leptin levels, increasing the drive to feed triggering neuroendocrine responses that limit energy expenditure (Ahima, Prabakaran et al. 1996; Bates and Myers 2003).
Leptin deficient (ob/ob) and leptin receptor deficient (db/db) mouse models have provided many insights into leptin signaling. Deficiency in leptin signaling causes a disruption in energy balance resulting in obesity from hyperphagia and decreased energy expenditure followed by the spontaneous development of insulin resistance (Ingalls, Dickie et al. 1950; Zhang, Proenca et al. 1994; Pelleymounter, Cullen et al. 1995). (Frederich, Hamann et al. 1995; Chua 1997). A similar phenotype is observed in humans with very rare mutations in the leptin or leptin receptor genes (Montague, Farooqi et al. 1997; Farooqi, Matarese et al. 2002; Farooqi and O'Rahilly 2006). With the exception of humans with this rare genetic leptin deficiency circulating leptin levels are positively correlated with adiposity (Frederich, Hamann et al. 1995). Obese individuals have elevated circulating leptin levels, but leptin fails to mediate weight loss, suggesting that most human obesity is a form of leptin resistance.
The leptin receptor (Ob-R) belongs to the cytokine receptor class I superfamily (Tartaglia 1997) and in the mouse is alternatively spliced into five known isoforms: Ob-Ra, Ob-Rb, Ob-Rc, Ob-Rd, and Ob-Re (Lee, Proenca et al. 1996). The longest isoform (Ob-Rb) is expressed at a high level in the hypothalamus and at a low level in other tissues including testes, adipose tissues, pancreatic β cells, heart, lung and lymph nodes (Ghilardi, Ziegler et al. 1996; Lee, Proenca et al. 1996; Emilsson, Liu et al. 1997; Fei, Okano et al. 1997; Lollmann, Gruninger et al. 1997; Spanswick, Smith et al. 1997). The Ob-Rb form is highly conserved among species and possesses an intracellular cytoplasmic domain of approximately 300 residues (Chen, Charlat et al. 1996; Lee, Proenca et al. 1996; Chua, Koutras et al. 1997; Tartaglia 1997). Ob-Rb, like other members of the cytokine receptor family mediates tyrosine kinase signaling by means of associated Janus kinase (Jak)/signal transducers and activators of transcription (STAT) pathway. Ob-Ra, Ob-Rc, Ob-Rd and Ob-Re are considered ‘short isoforms’, since they lack the long cytoplasmic domain. Ob-Ra-d contain identical extracellular leptin binding and transmembrane domains as well as the same first 29 intracellular amino acids and diverge in sequence secondary to alternative splicing of 3’ exons (Chua, Chung et al. 1996). The short isoform Ob-Ra is ubiquitously expressed (Lollmann, Gruninger et al. 1997) with particularly high expression in the choroid plexus and microvessels in the CNS and has been suggested to play a role in the transport of leptin across the blood brain barrier (Golden, Maccagnan et al. 1997; Tartaglia 1997; Wu-Peng, Chua et al. 1997). Ob-Re is a secreted isoform (Tartaglia 1997) that forms a complex with circulating leptin suggested to act as a buffering system to regulate leptin availability (Lollmann, Gruninger et al. 1997; Ge, Huang et al. 2002). The other functions of the short isoforms of the leptin receptor have yet to be determined.
The db/db mouse has a mutation in the signaling C terminus of the leptin receptor gene that results in a non-functional truncated long form of Ob-Rb (Hummel, Dickie et al. 1966; Chen, Charlat et al. 1996; Lee, Proenca et al. 1996). Central or peripheral administration of leptin in db/db mice has no effect on food intake or body weight (Halaas, Gajiwala et al. 1995). Since db/db mice express all the other short leptin receptor isoforms besides Ob-Rb, yet still develop the obese phenotype, it has been hypothesized that the weight controlling effects of leptin in mice are mediated by signaling through the long leptin receptor isoform, Ob-Rb. Furthermore, leptin activation of STAT3 occurs only in wild-type (WT) and ob/ob mice but not in db/db mice (Vaisse, Halaas et al. 1996). However, a recent study on leptin signaling showed that leptin stimulation of interleukin 1 beta (IL-1β) expression in the brain still occurs in db/db mice (Hosoi, Okuma et al. 2002). The possibility that leptin has effects in mice lacking the Ob-Rb isoform indicates that the short leptin receptor isoforms could play a yet undetermined role in leptin signaling.
In this present study we have characterized a transgenic mouse model of obesity that lacks all known isoforms of the leptin receptor on a C57BL/6 background. These db333/db333 mice, were isolated from an ENU mutagenesis screen and have a T to A transversion in the 7th coding exon of the leptin receptor, causing a premature stop codon: Y333stop. We performed an extensive endocrine and metabolic characterization of this transgenic mouse model of obesity in relation to the well characterized db/db mouse lacking just the long form of the leptin receptor.
Animals and surgery
Genetically obese C57BL/6 mice were generated in the laboratory of Dr. Bruce Beutler (The Scripps Research Institute, La Jolla, CA, USA) using ENU mutagenesis (Brown and Peters 1996). Positional cloning was used to determine the location of the point mutation in the leptin receptor gene. Both male db333/db333 and male WT littermates were fed ad libitum with mouse breeder diet composed of 11% fat, 17% Protein, 3.5% fiber (S-2335 Mouse Breeder, gross energy kcal 4.39kcal/g). Leprdb/Leprdb on a C57BL/6 background (stock number 000697) were obtained from Jackson laboratories. Groups of 5 mice of each genotype were used in all experiments at an age of 6–8 months unless otherwise stated.
Mice were anesthetized with isofluorane (induction 3–5%, maintenance 1.0%) and implanted with transmitter devices (TA10TA-F20; Data Sciences, Arden Hills, MN) into the peritoneal cavity. Transmitter devices contain sensors that measure core body temperature (CBT) and locomotor activity. Mice were allowed to recover for 1 week and then submitted to a second surgery. After anesthesia (induction 3–5%, maintenance 0.9– 1.5%), mice were placed into a stereotaxic apparatus. The skull was exposed, and holes were drilled to accommodate stereotaxic placement of a guide cannula (26 Ga, 1.0-cm length) aiming at the lateral ventricle (anterior–posterior from bregma, 0.3 mm; lateral, 1.0 mm; and ventral, 1.7 mm).
Mice with ad libitum access to food and water were monitored using a computer-controlled, open-circuit system (Oxymax System) that is part of an integrated Comprehensive Lab Animal Monitoring System (CLAMS; Columbus Instruments, Columbus, OH). Mice were singly-housed in clear respiratory chambers (20 × 10 × 12.5 cm) with a stainless steel elevated wire floor. Each of these chambers is equipped with a sipper tube delivering water and a food tray connected to a balance. Room air was passed through chambers at a flow rate of ~0.5 L/min. Exhaust air from each chamber was sampled at 20-min intervals for 1 min. Sample air was sequentially passed through O2 and CO2 sensors (Columbus Instruments) for determination of O2 and CO2 content, from which measures of oxygen consumption (VO2) and carbon dioxide production (VCO2) are estimated. Outdoor air reference values are sampled after every 4 measurements. Gas sensors are calibrated prior to the onset of experiments with primary gas standards containing known concentrations of O2, CO2, and N2 (Airgas Puritan Medical, Ontario, CA). Respiratory exchange ratio (RER) was calculated as the ratio of carbon dioxide production (VCO2) to oxygen consumption (VO2). VO2 and VCO2 are corrected for estimated effective metabolic mass per Kleiber’s power function. Receiver plates (RPC-1; Data Sciences) positioned inside the chambers continuously monitored core body temperature and locomotor activity by means of a fully automated data acquisition system (Dataquest A.R.T., Data Sciences, Inc.) Mice were acclimated to the respiratory chambers for 4 days before the onset of study. Data are recorded under ambient room temperature clamped at 25°C, beginning from the onset of the dark cycle.
Genotyping
Genotyping of mice was carried out by PCR with 25 ng of genomic DNA isolated from tail clippings in 20 µl reaction mixtures containing 1× PCR buffer-Mg (Invitrogen), 0.2mM each of a mixture of deoxynucleoside triphosphates (Invitrogen), 1.5mM MgCl2 (Invitrogen), 1U of Taq DNA Polymerase (Invitrogen) and 0.5µM of each primer db333/db333-F 5’-GCTGGAAGCCTGTCGTACTCTTCA-3’ and db333/db333-R 5’-TACACTGCGTCATAGGTAAACTTCCCTC -3’. After an initial denaturation at 94°C for 3 min, 35 cycles of PCR at 94°C for 45 s, 55°C for 30 s, and 72°C for 1min were performed, followed by a final extension at 72°C for 10 min. The PCR products were purified using a QIAquick PCR purification kit (Qiagen) and sequenced to identify homozygous mutant db333/db333 mice.
Analysis of fat depots and organ weights
Mice were anesthesized with 5% isoflurane and subsequently sacrificed. Wet fat pads (omental, mesenteric, subcutaneous and brown adipose tissue) and the liver were weighed immediately.
Measurement of food intake in response to leptin
Mice were given leptin (Peprotech, Rocky Hill, New Jersey) injections (4µg/uL, intracerebroventricular, icv) at 3:00 pm, prior to the onset of the dark cycle at 6:00 pm. An internal cannula (33 Ga, 1.1cm length) connected to plastic tubing and a microsyringe (10 µl) was used for direct delivery into the lateral ventricle. A volume of 1.0 µl (leptin or heat inactivated leptin, 98°C for 30 mins) was injected in a period of 5 min to allow for diffusion. Food intake was measured by weighing the amount of food eaten and normalized to initial body weight using the Kleiber’s function of 0.75.
Measurement of endocrine parameters
Mice were anesthetized with 5% isoflurane and blood samples were collected via retro-orbital bleeds with EDTA coated capillary tubes (Drummond, Broomall, PA, USA) into EDTA coated vials (Microvette, Germany). Samples were spun down at 1000 × g for 10 min and plasma was stored at −80 °C until analysis. Circulating levels of insulin, leptin and IL-6 were determined using the mouse serum adipokine kit (Millipore, St. Charles, MO, USA). Circulating levels of interleukin-1 receptor antagonist (IL-1Ra) were determined using the Immunoassay (R&D systems, Minneapolis, MN). All endocrine measurements were performed on plasma samples from mice at 6 months of age.
Insulin tolerance test
The glucose reducing effect of insulin injection was assessed in non fasted mice. Baseline glucose levels are measured by withdrawing ~0.6 uL of blood from the tail from unanesthesized mice before a load of human insulin was administered (1 unit/kg, i.p.; Sigma–Aldrich, St. Louis, MO). Further samples were collected 15, 30, 60, 90 and 120 mins after the insulin challenge. Blood glucose levels (in mg per deciliter) were determined by a glucometer (Glucometer, Rite Aid).
Glucose tolerance test
Mice were fasted for 16hrs overnight and injected intraperitoneally (i.p) with glucose (D-glucose, anhydrous; Sigma–Aldrich, St. Louis, MO) (1.5 mg/g body weight) in sterile water. Blood samples were taken before the glucose administration and then 15, 30, 60, 90 and 120 min after injection). Blood glucose levels were determined by a glucometer (Glucometer, Rite Aid).
Data Analysis
The significance of the difference in values between db333/db333, db/db and WT mice was evaluated using a one way ANOVA followed by Tukey's Honestly Significant Difference (HSD) test. For comparison of just db333/db333 and WT mice a two tailed independent T test was applied. The statistical significance was at the P<0.05 level. Data are expressed as means ± SE.
db333/db333 mice lack all leptin receptor isoforms due to a premature stop codon
db333/db33 mice were identified from an ENU mutagenesis screen and a positional cloning strategy was used to determine the location of the point mutation in the leptin receptor gene (Fig. 1A). The specific mutation is a T to A transversion in the 7th coding exon, causing a premature stop codon: Y333Stop (TAT→TAA). This premature stop codon causes biosynthesis of a truncated leptin receptor. Since the stop codon is upstream of the leptin receptor isoform splice sites, the mice lack earlier described long and short isoforms of the leptin receptor, see Fig.1B.
Figure 1
Figure 1
A. The db333/db333 mutation. DNA sequence chromatograms from homozygous mutant db333/db333 mice (TAA/TAA), heterozygous db333/db333 mice (TAA/TAT) and C57Bl/6 WT mice (TAT/TAT). db333/db333 mice have a point mutation in the leptin receptor gene causing (more ...)
db333/db333 mice are obese and hyperphagic and exhibit altered endocrine and inflammatory parameters associated with obesity
db333/db333 mice develop an extreme obese phenotype on normal chow (Fig. 2A). At 6 mths of age db333/db333 mice have significantly higher body weights compared with WT littermates (db333/db333 65.0 ± 5.9g, WT 36.25 ± 1.70g, P<0.05) (Fig. 2B). db333/db333 mice have significantly increased quantities of omental, mesenteric and subcutaneous fat, brown adipose tissue (BAT) and higher liver mass than WT littermates (Fig. 2C). db333/db333 mice are hyperphagic and consume significantly more food than WT littermates throughout the 24hr monitoring period (Fig 2D), with the most significant increase in food intake in db333/db333 mice in the dark cycle (db333/db333 3.95g ± 0.12, WT 2.24 ± 0.05g, P<0.05). (Fig. 2E). db333/db333 mice had significantly elevated circulating levels of leptin, insulin and IL-1Ra compared with WT littermates at 6 mths of age, (Table 1). db333/db333 also display significantly elevated insulin levels and show a trend towards higher IL-1Ra levels when compared with db/db mice. Levels of the pro-inflammatory cytokine interleukin 6 (IL-6) was also elevated in db333/db333 and db/db mice relative to levels in WT, lean littermates.
Figure 2
Figure 2
Phenotypic characterization of the db333/db333 mice
Table 1
Table 1
db333/db333 mice had significantly elevated circulating levels of leptin, insulin and interleukin-1 receptor antagonist (IL-1Ra) at 6 months of age when compared with WT lean littermates
db333/db333 mice display a trend of consistently higher body weights than db/db mice
Both db333/db333 and db/db mice have significantly greater body weights than WT littermates from as early as 4 weeks of age and throughout this monitoring period of 24wks (db333/db333 65.0 ± 5.9g; db/db 60.25 ± 1.38g, WT 36.25 ± 1.70g at 24wks), (Fig. 3). db333/db333 mice display consistently higher body weights than db/db mice from 8 wks to 24wks of age but this trend only reached statistical significance at one time point (12wk).
Figure 3
Figure 3
Growth curve of male db333/db333, db/db and WT mice
db333/db333 and db/db mice show decreased insulin sensitivity & impaired glucose tolerance relative to lean mice
Intraperitoneal administration of insulin (1 unit per kg of body weight) revealed that both db333/db333 and db/db mice have an impaired glucose disposal ability relative to the hypoglycemic response to insulin observed in the WT littermates (Fig 4A). The ability of insulin to acutely stimulate glucose mobilization was significantly blunted at 30 mins in db333/db333 and db/db mice relative to WT littermates. Both db333/db333 and db/db mice exhibit impaired glucose disposal when challenged with glucose (1.5 mg of glucose per gram of body weight), Fig. 4B. Significant differences in glucose disposal between db333/db333 mice and WT littermates were observed at 15 mins and 60 mins after glucose injection.
Figure 4
Figure 4
A. Insulin sensitivity test in db333/db333, db/db and WT mice. Intraperitoneal insulin administration (1 unit per kg of body weight) revealed that both db333/db333 and db/db mice have an impaired glucose disposal ability relative to the hypoglycemic response (more ...)
db333/db333 mice have a lower core body temperature and decreased locomotor activity relative to WT littermates
db333/db333 and db/db mice display a significantly lower core body temperature, as determined by radiotelemetry, relative to lean mice (Fig 5A). Average core body temperature over both the 12hr light or dark cycle in db333/db333 and db/db mice is significantly lower when compared with lean mice (Fig 5B). db333/db333 and db/db mice display decreased locomotor activity relative to WT mice although there is a modest difference in activity between db333/db333 and db/db mice towards the end of the dark cycle (Fig 5C). During the dark cycle db/db and db333/db333 mice show significantly reduced activity relative to WT littermates (p< 0.05) Fig 5D.
Figure 5
Figure 5
Core Body Temperature and spontaneous locomotor activity in db333/db333, db/db and WT mice during a 24hr monitoring period
Functional loss of the leptin receptor in db333/db333 mice
The functional loss of leptin signaling in db333/db333 and db/db mice was determined by comparison with leptin induced reduction in food intake in WT littermates. Injection of leptin (icv 4 µg/µL) caused a significant reduction in food intake in WT mice while no significant appetite suppression was observed in db333/db333 or db/db mice (Fig 6).
Figure 6
Figure 6
Effects of icv leptin administration on food intake in db333/db333, db/db and WT mice
db333/db333 and db/db mice showed significantly lower oxygen consumption, carbon dioxide production and respiratory efficiency ratio compared with lean mice
Measurements of O2 production (VO2) and CO2 production (VCO2) were acquired from each metabolic chamber every 20mins and sent to a computer which collects and processes the data continuously over a 24hr monitoring period. Both db/db and db333/db333 mice displayed significantly lower oxygen consumption (Fig. 7A) and carbon dioxide production (Fig. 7B) at all time points throughout both the light and dark cycle relative to lean mice (P<0.05). Respiratory Efficiency Ratio (RER) (VCO2/ VO2) in both db333/db333 and db/db showed a trend of lower RER relative to WT mice that is most pronounced in the dark cycle indicating a trend to the use of lipids as energy substrates in these obese mutants. db333/db333 mice also show a consistently lower RER relative to db/db although this trend was not deemed statistically significant (Fig 7C).
Figure 7
Figure 7
Metabolic comparison of db333/db333, db/db and WT mice during a 24hr monitoring period
We have characterized a newly generated mouse model of obesity, the db333/db333 mice, deficient in all known leptin receptor isoforms in mice. db333/db333 mice have a point mutation in the seventh exon of the db gene encoding the leptin receptor resulting in a premature stop codon (Y333Stop) upstream of all the known splice sites. db333/db333 mice have a morbidly obese phenotype, with body weights diverging from WT as early as 4 weeks of age. The obese phenotype of the db333/db333 mice is caused not only by hyperphagia but also by disrupted neuroendocrine regulation of energy expenditure. db333/db333 mice had significantly elevated circulating levels of leptin, insulin and interleukin-1 receptor antagonist as also observed in human diabetics and mouse models of obesity (Ludvik, Kautzky-Willer et al. 1997; Luheshi, Gardner et al. 1999; Meier, Bobbioni et al. 2002; Juge-Aubry, Somm et al. 2003; Somm, Henrichot et al. 2005; Somm, Cettour-Rose et al. 2006).
This study describes an extensive in-vivo metabolic comparison of the db333/db333 mice lacking all forms of the leptin receptor with the db/db mice lacking just the Ob-Rb long isoform of the receptor (Chen, Charlat et al. 1996). The functional loss of leptin signaling in db333/db333 and db/db mice was confirmed by icv administration of leptin which resulted in significant reduction in food intake in WT mice while, as expected, no significant appetite suppression was observed in db333/db333 or db/db mice. Both db333/db333 and db/db mice are obese, hyperphagic and insulin resistant. The metabolic comparison of these obese leptin receptor deficient mice with lean mice showed that db333/db333 and db/db mice consume significantly less O2 and produce significantly less CO2 in comparison with lean controls as observed in other obese mutants (Pelleymounter, Cullen et al. 1995; Overton, Williams et al. 2001). Neither db333/db333 or db/db mice display the classical circadian rhythm of lower oxygen demand and CO2 production in the light cycle and markedly higher O2 demand and CO2 production in the dark cycle as seen in lean controls. The reduced Respiratory Efficiency Ratio (RER) in both db333/db333 and db/db mice indicates the use of lipids as energy substrates in these mice as opposed to carbohydrates in WT mice as suggested by an RER closer to 1. The activity levels observed in db333/db333 and db/db mice are dramatically reduced compared with WT animals. db333/db333 and db/db mice also maintain a consistently lower core body temperature of approximately 35°C consistent with previous findings in these Ob-Rb deficient mice (Trayhurn and James 1978; Harris, Mitchell et al. 2001). However a modest increase in activity was observed in db333/db333 mice relative to db/db mice towards the end of the dark cycle in comparison with db/db mice. This trend of increase in activity has previously been described in the s/s mutant mouse that has a Tyr to Ser mutation at position 1138 of the db gene that specifically disrupts the activation of the transcription factor STAT3 (Bates, Dundon et al. 2004). In both the db333/db333 and s/s mutant mouse neither the core body temperature, VO2 consumption or CO2 production were different from that observed in db/db mice at this time point suggesting this modest increase in activity in the dark phase does not significantly alter overall energy expenditure.
Ob-Rb is believed to function through a Jak/STAT signal transduction pathway (Ghilardi, Ziegler et al. 1996) to promote fat oxidation (Hwa, Ghibaudi et al. 1996) satiety (Satoh, Ogawa et al. 1998) and the homeostasis of lipids (Unger, Zhou et al. 1999). Leptin signaling in hypothalamic neurons results in a decrease in feeding and an increase in energy expenditure in order to maintain energy homeostasis. (Campfield, Smith et al. 1995; Halaas, Gajiwala et al. 1995; Levin, Nelson et al. 1996). In states of negative energy balance such as starvation, a decrease in leptin levels causes an increase in food intake and a decrease in energy expenditure (Elmquist, Maratos-Flier et al. 1998; Friedman and Halaas 1998). Therefore, lack of the leptin signaling in these mice results in early onset obesity secondary to the increase in feeding and decreased energy utilization.
db333/db333 mice have altered endocrine and metabolic parameters consistent with previously described leptin receptor deficient mouse models of obesity including db/db mice that lack only the Ob-Rb isoform (Chen, Charlat et al. 1996; Myers 2004) and several other mutants described that lack all known isoforms of the leptin receptor (Aubert, Herzog et al. 1985; Lee, Li et al. 1997; Li, Ioffe et al. 1998). For example the db3J/db3J mouse has a frameshift mutation at amino acid 625 (Leiter, Coleman et al. 1980) (Lee, Li et al. 1997) (Luo, Liu et al. 2006). and the dbPas/dbPas mouse has a duplication of exons 4 and 5 of Ob-R which introduces a premature stop codon at residue 281 (Li, Ioffe et al. 1998). Both mutations result in a truncated receptor without a transmembrane domain and results in complete ablation of all known leptin receptor splice variants (Fig. 1B).
The db333/db333 mice display very similar obese phenotypes to the other leptin receptor deficient mouse models of obesity. The C57BL/6 db3J/db3J mice gain weight in an identical manner to db333/db333 mice, for example at 12 wks of age C57BL/6 db3J/db3J mice weigh 56g ± 7.4 (Luo, Liu et al. 2006) and db333/db333 mice weigh 55.5g ± 2.3. The dbPas/ dbPas mice have a similar weight gain profile as the db333/db333 mice, at 24wks of age, dbPas/ dbPas weigh 67.3g ± 1.71 compared with db333/db333 that weigh 68.6g ± 5.96 (Aubert, Herzog et al. 1985).
The db333/db333 and db/db mice display very similar metabolic phenotypes in this study. Therefore, this study further confirms the finding that the long cytoplasmic domain of the leptin receptor is the main isoform by which leptin exerts its effects on energy homeostasis (Ghilardi, Ziegler et al. 1996). However, there is trend towards higher body weight, higher insulin and IL1Ra levels, lower CO2, VO2, RER and temperature in db333/db333 mice when compared with db/db mice which raises the question whether the short forms of the receptor play an additional role in energy homeostasis. Transgenic replacement of the long form of the leptin receptor (Ob-Rb) that is restricted to neurons in db3J/db3J animals has been shown to partially rescue the obesity/diabetes phenotype while fully correcting the impaired thermoregulatory thermogenesis phenotype (Kowalski, Liu et al. 2001). This partial attenuation of the obesity/diabetes phenotype (including body weight, circulating leptin, glucose and insulin) without a full restoration of WT levels, may be reflective of a role of the shorter isoforms in energy homeostasis.
In summary, we have characterized a novel transgenic mouse model of obesity, the db333/db333 mice, with a mutation that ablates expression of all leptin receptor variants. This db333/db333 mouse may prove useful in future studies on the roles of the long form and the short form of leptin receptors respectively.
Acknowledgements
These studies were supported by funds from The Harold L Dorris Neurological Institute endowment, grants from the Skaggs Institute of Chemical Biology and from the Ellison Foundation AG-SS 1705-06 and NIH R01 AG028040. The original publication is available at www.springerlink.com.
  • Ahima RS, Dushay J, et al. Leptin accelerates the onset of puberty in normal female mice. J Clin Invest. 1997;99(3):391–395. [PMC free article] [PubMed]
  • Ahima RS, Prabakaran D, et al. Role of leptin in the neuroendocrine response to fasting. Nature. 1996;382(6588):250–252. [PubMed]
  • Aubert R, Herzog J, et al. Description of a new model of genetic obesity: the dbPas mouse. J Nutr. 1985;115(3):327–333. [PubMed]
  • Bates SH, Dundon TA, et al. LRb-STAT3 signaling is required for the neuroendocrine regulation of energy expenditure by leptin. Diabetes. 2004;53(12):3067–3073. [PubMed]
  • Bates SH, Myers MG., Jr. The role of leptin receptor signaling in feeding and neuroendocrine function. Trends Endocrinol Metab. 2003;14(10):447–452. [PubMed]
  • Brown SD, Peters J. Combining mutagenesis and genomics in the mouse--closing the phenotype gap. Trends Genet. 1996;12(11):433–435. [PubMed]
  • Campfield LA, Smith FJ, et al. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science. 1995;269(5223):546–549. [PubMed]
  • Chehab FF, Lim ME, et al. Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. Nat Genet. 1996;12(3):318–320. [PubMed]
  • Chen H, Charlat O, et al. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell. 1996;84(3):491–495. [PubMed]
  • Chua SC., Jr. Monogenic models of obesity. Behav Genet. 1997;27(4):277–284. [PubMed]
  • Chua SC, Jr., Chung WK, et al. Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science. 1996;271(5251):994–996. [PubMed]
  • Chua SC, Jr., Koutras IK, et al. Fine structure of the murine leptin receptor gene: splice site suppression is required to form two alternatively spliced transcripts. Genomics. 1997;45(2):264–270. [PubMed]
  • Elmquist JK, Maratos-Flier E, et al. Unraveling the central nervous system pathways underlying responses to leptin. Nat Neurosci. 1998;1(6):445–450. [PubMed]
  • Emilsson V, Liu YL, et al. Expression of the functional leptin receptor mRNA in pancreatic islets and direct inhibitory action of leptin on insulin secretion. Diabetes. 1997;46(2):313–316. [PubMed]
  • Farooqi IS, Matarese G, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest. 2002;110(8):1093–1103. [PMC free article] [PubMed]
  • Farooqi S, O'Rahilly S. Genetics of obesity in humans. Endocr Rev. 2006;27(7):710–718. [PubMed]
  • Fei H, Okano HJ, et al. Anatomic localization of alternatively spliced leptin receptors (Ob-R) in mouse brain and other tissues. Proc Natl Acad Sci U S A. 1997;94(13):7001–7005. [PubMed]
  • Frederich RC, Hamann A, et al. Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat Med. 1995;1(12):1311–1314. [PubMed]
  • Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature. 1998;395(6704):763–770. [PubMed]
  • Ge H, Huang L, et al. Generation of soluble leptin receptor by ectodomain shedding of membrane-spanning receptors in vitro and in vivo. J Biol Chem. 2002;277(48):45898–45903. [PubMed]
  • Ghilardi N, Ziegler S, et al. Defective STAT signaling by the leptin receptor in diabetic mice. Proc Natl Acad Sci U S A. 1996;93(13):6231–6235. [PubMed]
  • Golden PL, Maccagnan TJ, et al. Human blood-brain barrier leptin receptor. Binding and endocytosis in isolated human brain microvessels. J Clin Invest. 1997;99(1):14–18. [PMC free article] [PubMed]
  • Halaas JL, Gajiwala KS, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science. 1995;269(5223):543–546. [PubMed]
  • Harris RB, Mitchell TD, et al. Metabolic responses to leptin in obese db/db mice are strain dependent. Am J Physiol Regul Integr Comp Physiol. 2001;281(1):R115–R132. [PubMed]
  • Heiman ML, Ahima RS, et al. Leptin inhibition of the hypothalamic-pituitary-adrenal axis in response to stress. Endocrinology. 1997;138(9):3859–3863. [PubMed]
  • Hosoi T, Okuma Y, et al. Leptin regulates interleukin-1beta expression in the brain via the STAT3-independent mechanisms. Brain Res. 2002;949(1–2):139–146. [PubMed]
  • Hummel KP, Dickie MM, et al. Diabetes, a new mutation in the mouse. Science. 1966;153(740):1127–1128. [PubMed]
  • Hwa JJ, Ghibaudi L, et al. Intracerebroventricular injection of leptin increases thermogenesis and mobilizes fat metabolism in ob/ob mice. Horm Metab Res. 1996;28(12):659–663. [PubMed]
  • Ingalls AM, Dickie MM, et al. Obese, a new mutation in the house mouse. J Hered. 1950;41(12):317–318. [PubMed]
  • Juge-Aubry CE, Somm E, et al. Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and inflammation. Diabetes. 2003;52(5):1104–1110. [PubMed]
  • Kowalski TJ, Liu SM, et al. Transgenic complementation of leptin-receptor deficiency. I. Rescue of the obesity/diabetes phenotype of LEPR-null mice expressing a LEPR-B transgene. Diabetes. 2001;50(2):425–435. [PubMed]
  • Lee G, Li C, et al. Leptin receptor mutations in 129 db3J/db3J mice and NIH facp/facp rats. Mamm Genome. 1997;8(6):445–447. [PubMed]
  • Lee GH, Proenca R, et al. Abnormal splicing of the leptin receptor in diabetic mice. Nature. 1996;379(6566):632–635. [PubMed]
  • Leiter EH, Coleman DL, et al. A new mutation (db3J) at the diabetes locus in strain 129/J mice. I. Physiological and histological characterization. Diabetologia. 1980;19(1):58–65. [PubMed]
  • Levin N, Nelson C, et al. Decreased food intake does not completely account for adiposity reduction after ob protein infusion. Proc Natl Acad Sci U S A. 1996;93(4):1726–1730. [PubMed]
  • Li C, Ioffe E, et al. Absence of soluble leptin receptor in plasma from dbPas/dbPas and other db/db mice. J Biol Chem. 1998;273(16):10078–10082. [PubMed]
  • Loffreda S, Yang SQ, et al. Leptin regulates proinflammatory immune responses. Faseb J. 1998;12(1):57–65. [PubMed]
  • Lollmann B, Gruninger S, et al. Detection and quantification of the leptin receptor splice variants Ob-Ra, b, and, e in different mouse tissues. Biochem Biophys Res Commun. 1997;238(2):648–652. [PubMed]
  • Lord GM, Matarese G, et al. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature. 1998;394(6696):897–901. [PubMed]
  • Ludvik B, Kautzky-Willer A, et al. Amylin: history and overview. Diabet Med. 1997;14 Suppl 2:S9–S13. [PubMed]
  • Luheshi GN, Gardner JD, et al. Leptin actions on food intake and body temperature are mediated by IL-1. Proc Natl Acad Sci U S A. 1999;96(12):7047–7052. [PubMed]
  • Luo N, Liu SM, et al. Allelic variation on chromosome 5 controls beta-cell mass expansion during hyperglycemia in leptin receptor-deficient diabetes mice. Endocrinology. 2006;147(5):2287–2295. [PubMed]
  • Meier CA, Bobbioni E, et al. IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin? J Clin Endocrinol Metab. 2002;87(3):1184–1188. [PubMed]
  • Montague CT, Farooqi IS, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature. 1997;387(6636):903–908. [PubMed]
  • Myers MG., Jr. Leptin receptor signaling and the regulation of mammalian physiology. Recent Prog Horm Res. 2004;59:287–304. [PubMed]
  • Overton JM, Williams TD, et al. Cardiovascular and metabolic responses to fasting and thermoneutrality are conserved in obese Zucker rats. Am J Physiol Regul Integr Comp Physiol. 2001;280(4):R1007–R10015. [PubMed]
  • Pelleymounter MA, Cullen MJ, et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science. 1995;269(5223):540–543. [PubMed]
  • Satoh N, Ogawa Y, et al. Satiety effect and sympathetic activation of leptin are mediated by hypothalamic melanocortin system. Neurosci Lett. 1998;249(2–3):107–110. [PubMed]
  • Schwartz MW, Baskin DG, et al. Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice. Diabetes. 1996;45(4):531–535. [PubMed]
  • Somm E, Cettour-Rose P, et al. Interleukin-1 receptor antagonist is upregulated during diet-induced obesity and regulates insulin sensitivity in rodents. Diabetologia. 2006;49(2):387–393. [PubMed]
  • Somm E, Henrichot E, et al. Decreased fat mass in interleukin-1 receptor antagonist-deficient mice: impact on adipogenesis, food intake, and energy expenditure. Diabetes. 2005;54(12):3503–3509. [PubMed]
  • Spanswick D, Smith MA, et al. Leptin inhibits hypothalamic neurons by activation of ATP-sensitive potassium channels. Nature. 1997;390(6659):521–525. [PubMed]
  • Tartaglia LA. The leptin receptor. J Biol Chem. 1997;272(10):6093–6096. [PubMed]
  • Trayhurn P, James WP. Thermoregulation and non-shivering thermogenesis in the genetically obese (ob/ob) mouse. Pflugers Arch. 1978;373(2):189–193. [PubMed]
  • Unger RH, Zhou YT, et al. Regulation of fatty acid homeostasis in cells: novel role of leptin. Proc Natl Acad Sci U S A. 1999;96(5):2327–2332. [PubMed]
  • Vaisse C, Halaas JL, et al. Leptin activation of Stat3 in the hypothalamus of wild-type and ob/ob mice but not db/db mice. Nat Genet. 1996;14(1):95–97. [PubMed]
  • Wu-Peng XS, Chua SC, Jr., et al. Phenotype of the obese Koletsky (f) rat due to Tyr763Stop mutation in the extracellular domain of the leptin receptor (Lepr): evidence for deficient plasma-to-CSF transport of leptin in both the Zucker and Koletsky obese rat. Diabetes. 1997;46(3):513–518. [PubMed]
  • Yu WH, Kimura M, et al. Role of leptin in hypothalamic-pituitary function. Proc Natl Acad Sci U S A. 1997;94(3):1023–1028. [PubMed]
  • Zhang Y, Proenca R, et al. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372(6505):425–432. [PubMed]